… in each study were the individual’s age, gender, social circumstances, number of urinary
tract infections, bladder symptoms, presence of co-morbidity, stage of multiple sclerosis and …

… pipeline used in our earlier CovRNN study. 20 This source code underwent minor modifications
to conform with Cosmos standards and the goals of this study. The core model used for …

… Oral cladribine is a highly effective pulsed selective immune reconstitution therapy licensed
for relapsing multiple sclerosis (RMS) since 2017. A full treatment course comprises two …

… with Multiple Sclerosis have been investigated, opening the doors to the hypothesis that in the
pathogenesis of multiple sclerosis … the correlation between Multiple Sclerosis and vascular …

… Oral cladribine is a highly effective pulsed selective immune reconstitution therapy licensed
for relapsing multiple sclerosis. A full treatment course comprises two treatment cycles given …

… multiple sclerosis patients has been previously reported to range between 3.86 and 8.11 [26].
In this study… Participants who reported at least one relapse during the study were excluded. …

… measures of disease activity in the phase II study in relapsing-remitting multiple sclerosis
(RRMS), and relapse rate in the pooled phase III studies in relapsing multiple sclerosis (RMS). …

… Questionnaire A is an adaptation from the COSMO study (27)… In the protocol template
of the COSMO study (27), it is stated … by the research group of the present study or more in-depth …

… , after a brain imaging (MRI) study, she was diagnosed with multiple sclerosis (MS), a chronic
… She wondered when the next Cosmopolitan magazine would arrive in the mail. She never …

… neurodegeneration in multiple sclerosis (MS). Erythropoietin, which is produced upon
exposure to hypoxia, is thought to act as a neuroprotective agent in MS. Therefore, we studied the …